Literature DB >> 21327431

Increased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis.

José Alexandre Mendonça1, João Francisco Marques-Neto, Adil Muhib Samara, Simone Appenzeller.   

Abstract

Targeted inhibition of tumor necrosis factor-α (TNF-α) is an effective therapy in rheumatoid arthritis (RA). In some rare cases, autoimmune phenomena, including drug-induced lupus and vasculitis, is described. However, the immunological mechanisms underlying the development of autoimmunity are unknown. We report 3 patients that developed autoimmune phenomena while in use of TNF-α inhibitor, showing concomitant increase in rheumatoid factor (RF). We hypothesize that the increase in RF several months prior to the occurrence of vasculitis may help identifying other patients at risk for the development of vasculitis secondary to these medications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327431     DOI: 10.1007/s00296-011-1812-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  13 in total

1.  Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis.

Authors:  Richard Day
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

2.  Clustering of extraarticular manifestations in patients with rheumatoid arthritis.

Authors:  Carl Turesson; Robyn L McClelland; Teresa Christianson; Eric Matteson
Journal:  J Rheumatol       Date:  2008-01       Impact factor: 4.666

3.  Drug-induced systemic lupus erythematosus associated with etanercept therapy.

Authors:  Najia Shakoor; Margaret Michalska; Charlotte A Harris; Joel A Block
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

Review 4.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

Review 5.  Vasculitis in rheumatoid arthritis.

Authors:  Carl Turesson; Eric L Matteson
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

6.  Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications.

Authors:  A J Geirsson; G Sturfelt; L Truedsson
Journal:  Ann Rheum Dis       Date:  1987-10       Impact factor: 19.103

7.  Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.

Authors:  Severine Vermeire; Maja Noman; Gert Van Assche; Filip Baert; Kristel Van Steen; Nele Esters; Sofie Joossens; Xavier Bossuyt; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

8.  Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Sandra Muñoz; Natalia Soria; Diana Galiana; Laura Bertolaccini; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Medicine (Baltimore)       Date:  2007-07       Impact factor: 1.889

9.  Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.

Authors:  Stephen J Jarrett; Gaye Cunnane; Philip G Conaghan; Sarah J Bingham; Maya H Buch; Mark A Quinn; Paul Emery
Journal:  J Rheumatol       Date:  2003-10       Impact factor: 4.666

10.  Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.

Authors:  Marcel Flendrie; Wynand H P M Vissers; Marjonne C W Creemers; Elke M G J de Jong; Peter C M van de Kerkhof; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2005-04-04       Impact factor: 5.156

View more
  2 in total

Review 1.  Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.

Authors:  Karin A van Schie; Gerrit-Jan Wolbink; Theo Rispens
Journal:  MAbs       Date:  2015       Impact factor: 5.857

2.  Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome.

Authors:  Shanti Virupannavar; Anthony Brandau; Carla Guggenheim; Heather Laird-Fick
Journal:  Case Rep Rheumatol       Date:  2014-05-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.